Synopsys chair sells 49,641 shares after exercise
Synopsys’ executive chair exercised 49,641 options and sold an equal number of shares under a pre-set Rule 10b5-1 plan.
Rhea-AI Filing Summary
SYNOPSYS INC (SNPS) reports that Executive Chair Aart de Geus exercised and sold company equity over August 31 and September 1, 2026. He exercised in total 49,641 non-qualified stock options at an exercise price of $135.88 per share to acquire the same number of common shares, then sold 25,000 shares at a weighted average price of $441.7646 and 24,641 shares at a weighted average price of $419.4401 in open-market transactions. He also acquired 22 shares through the Synopsys Employee Stock Purchase Plan. All reported transactions were effected under a Rule 10b5-1 trading plan adopted October 14, 2025. Indirect holdings after these transactions include 308,791 shares held by a Family Trust and 14,500 shares held by a Partnership.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 49,641 shares ($14.63M approx. pre-tax spread)
Exercise and Sale
9 txns
Insider
DE GEUS AART
Role
EXECUTIVE CHAIR
Sold
49,641 shs ($21.38M)
Approx. gross sale proceeds
$21.38M
Approx. exercise cost
$6.75M
Approx. pre-tax spread
$14.63M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (right to buy) F4 | 24,641 | $0.00 | $0.00 |
| Exercise | Common Stock | 24,641 | $135.88 | $3.35M |
| Sale | Common Stock F3 | 24,641 | $419.4401 | $10.34M |
| Exercise | Non-Qualified Stock Option (right to buy) F4 | 25,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 25,000 | $135.88 | $3.40M |
| Sale | Common Stock F1 | 25,000 | $441.7646 | $11.04M |
| Other | Common Stock F2 | 22 | $360.961 | $8K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Non-Qualified Stock Option (right to buy) — 0 contracts (Direct);
Common Stock — 120,443 shares (Direct);
Common Stock — 308,791 shares (Indirect, by Family Trust);
Common Stock — 14,500 shares (Indirect, by Partnership)
Footnotes (4)
- F1. Represents a weighted average sale price per share. These shares were sold in multiple transactions at prices ranging from $435.88 to $445.70. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range.
- F2. Acquisition of stock under Synopsys, Inc Employee Stock Purchase Plan
- F3. Represents a weighted average sale price per share. These shares were sold in multiple transactions at prices ranging from $413.99 to $430.26. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range.
- F4. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted October 14, 2025.
Key Figures
Options exercised: 49,641 shares
Option exercise price: $135.88 per share
Shares sold August 31, 2026: 25,000 shares at $441.7646 per share
+5 more
8 metrics
Options exercised
49,641 shares
Non-qualified stock options exercised on August 31 and September 1, 2026
Option exercise price
$135.88 per share
Exercise price for non-qualified stock options into Synopsys common stock
Shares sold August 31, 2026
25,000 shares at $441.7646 per share
Open-market sale at weighted average price
Shares sold September 1, 2026
24,641 shares at $419.4401 per share
Open-market sale at weighted average price
Employee Stock Purchase Plan acquisition
22 shares at $360.961 per share
Acquisition under Synopsys, Inc. Employee Stock Purchase Plan
Indirect holdings by Family Trust
308,791 shares
Indirect ownership of Synopsys common stock as of August 31, 2026
Indirect holdings by Partnership
14,500 shares
Indirect ownership of Synopsys common stock as of August 31, 2026
Rule 10b5-1 plan adoption date
October 14, 2025
Plan governing the reported transactions
Key Terms
Non-Qualified Stock Option, Rule 10b5-1 trading plan, weighted average sale price, Employee Stock Purchase Plan
4 terms
Non-Qualified Stock Option financial
"security titled "Non-Qualified Stock Option (right to buy)""
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
Rule 10b5-1 trading plan regulatory
"transactions were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sale price financial
"Represents a weighted average sale price per share"
Employee Stock Purchase Plan financial
"Acquisition of stock under Synopsys, Inc Employee Stock Purchase Plan"
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
FAQ
What did Synopsys (SNPS) Executive Chair Aart de Geus report on this Form 4?
He exercised 49,641 stock options at $135.88 per share to receive the same number of common shares and then sold all 49,641 shares in open-market transactions on August 31 and September 1, 2026.
Were the SNPS transactions by Aart de Geus under a Rule 10b5-1 plan?
Yes. Aart de Geus’ reported option exercises and share sales were effected under a Rule 10b5-1 trading plan that was adopted on October 14, 2025, as disclosed in the filing’s footnotes.
What indirect Synopsys (SNPS) holdings does Aart de Geus report after these transactions?
He reports indirect ownership of 308,791 shares of Synopsys common stock held by a Family Trust and 14,500 shares held by a Partnership, as of August 31, 2026.
What type of options did Aart de Geus exercise in this Synopsys (SNPS) Form 4?
He exercised non-qualified stock options (right to buy), covering 49,641 underlying shares of Synopsys common stock, at an exercise price of $135.88 per share, with the options expiring on December 12, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
